Analysts Set Tempus AI, Inc. (NASDAQ:TEM) Target Price at $68.92

Tempus AI, Inc. (NASDAQ:TEM) has been given an average rating of “Hold” by the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $68.9231.

Several research analysts have commented on TEM shares. Guggenheim raised their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Freedom Capital raised Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Finally, Jefferies Financial Group began coverage on Tempus AI in a research note on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective for the company.

Insider Transactions at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 4,116 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the sale, the chief accounting officer owned 74,041 shares of the company’s stock, valued at $3,262,986.87. This trade represents a 5.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares of the company’s stock, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 699,793 shares of company stock worth $33,763,231. 24.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently bought and sold shares of the stock. JPL Wealth Management LLC bought a new position in shares of Tempus AI in the 3rd quarter worth $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Tempus AI during the 3rd quarter valued at $38,000. Danske Bank A S bought a new stake in shares of Tempus AI during the 3rd quarter worth $48,000. Finally, Sunbelt Securities Inc. bought a new stake in shares of Tempus AI during the 3rd quarter worth $52,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $43.87 on Wednesday. The company has a 50 day moving average of $51.40 and a 200 day moving average of $52.59. The stock has a market cap of $7.88 billion, a P/E ratio of -30.47 and a beta of 3.58. Tempus AI has a 12 month low of $40.77 and a 12 month high of $104.32. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the prior year, the firm posted ($0.22) EPS. Tempus AI’s revenue was up 21.6% on a year-over-year basis. As a group, sell-side analysts forecast that Tempus AI will post -1.35 EPS for the current fiscal year.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q2 results beat expectations. Tempus reported an adjusted loss of $0.04 per share, narrower than the $0.14 consensus loss and improved from a $0.22 loss a year earlier. Revenue increased 21.6% year over year to $382.5 million, modestly above estimates. Tempus AI Q2 earnings report
• Positive Sentiment: Management raised or reaffirmed strong 2026 growth expectations. Full-year revenue guidance is approximately $1.595 billion to $1.605 billion, supported by momentum in oncology diagnostics, data and modeling. Tempus also outlined a potential $400 million revenue uplift by 2028 tied to its xT CDx and xF products. Tempus revenue outlook
• Positive Sentiment: Analyst support remains favorable. Needham reaffirmed its Buy rating and set a $75 price target, implying substantial upside from recent trading levels. Needham analyst rating
• Negative Sentiment: The earnings beat did not fully resolve profitability concerns. Tempus remains unprofitable, with a negative net margin and analysts projecting a full-year loss. Revenue guidance is broadly consistent with expectations rather than a major upside surprise, contributing to the post-earnings reset. Tempus earnings call highlights
• Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares. The $10.5 million sale reduced his direct holdings by more than half. Although it was conducted under a pre-arranged Rule 10b5-1 plan, the transaction can still weigh on sentiment, particularly while the stock trades well below its 52-week high. Tempus CEO stock sale

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.